{"nctId":"NCT04285515","briefTitle":"Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder","startDateStruct":{"date":"2020-02-27","type":"ACTUAL"},"conditions":["Bipolar Depression","Major Depressive Disorder"],"count":488,"armGroups":[{"label":"Lumateperone 42mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lumateperone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Lumateperone","otherNames":[]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Major Inclusion Criteria:\n\n* Male or female subjects of any race, ages 18-75 inclusive\n* Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD\n* The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)\n* Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)\n* The patient meets the DSM-5 criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis\n* Current major depressive episode is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning\n* Able to provide written informed consent\n\nMajor Exclusion Criteria:\n\n* Any female subject who is pregnant or breast-feeding\n* Any subject judged to be medically inappropriate for study participation\n* The patient has a significant risk for suicidal behavior\n* The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.1","spread":"0.71"},{"groupId":"OG001","value":"-12.4","spread":"0.70"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"1.00"},{"groupId":"OG001","value":"-12.0","spread":"0.96"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.2","spread":"0.95"},{"groupId":"OG001","value":"-12.2","spread":"0.96"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"0.64"},{"groupId":"OG001","value":"-12.1","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)","description":"The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.08"},{"groupId":"OG001","value":"-1.2","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)","description":"The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.11"},{"groupId":"OG001","value":"-1.2","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)","description":"The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.11"},{"groupId":"OG001","value":"-1.1","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)","description":"The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.07"},{"groupId":"OG001","value":"-1.1","spread":"0.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":240},"commonTop":["Headache","Somnolence","Dizziness","Nausea"]}}}